Advertisement

---

ARENA PHARMACEUTICALS, INC.

Arena Pharmaceuticals Announces BELVIQ™ (lorcaserin HCl) New Drug Submission in Canada

[2013-06-26] - -- Eisai's Application for Approval as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena --


Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference

[2013-06-14] -


BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013

[2013-06-14] -


Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese

[2013-06-07] - -- BELVIQ Available in US Pharmacies within One Week --
-- Arena Achieves $65 Million in Milestones and is Eligible for Additional Payments Based on Product Sales --


Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences

[2013-05-24] -


Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

[2013-05-10] -


Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ® (lorcaserin HCl) for Chronic Weight Management

[2013-05-07] - -- Arena to Receive $65 Million in Milestone Payments from Eisai --


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers